Tecovirimat (TPOXX) is the primary antiviral treatment for mpox, available through clinical trials and expanded access programs for severe cases.

Recent study in Democratic Republic of Congo showed tecovirimat didn't reduce lesion duration, but highlighted the importance of supportive care in improving outcomes.

Additional therapeutics like brincidofovir, Vaccinia Immune Globulin (VIGIV), and cidofovir are available for certain complex cases or when tecovirimat is ineffective.

People with advanced HIV are at higher risk for severe mpox, prompting CDC to launch a study (VIRISMAP) to understand viral spread and immune responses in this population.

The STOMP clinical trial is ongoing to assess tecovirimat's efficacy, particularly in immunocompromised patients and those at high risk for severe disease.